Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Chemed: 3 Key Takeaways for Long-Term Investors

Brand strength and operational scale may offset near-term margin pressure from strategic acquisitions and rising marketing costs.

Chemed (CHE -0.05%) disclosed during its Q3 2026 earnings call on October 28, 2026, that it anticipates full-year adjusted earnings per share (EPS) to reach or exceed the upper limit of its prior guidance. The company's diverse business model, encompassing end-of-life care and nationwide residential plumbing services, provides consistent operational cash flow to finance share buybacks and strategic franchise acquisitions.

In 2026, Chemed spent $96 million to acquire Roto-Rooter franchise territories in California and Texas. Initially, these territories exhibited lower earnings before interest, taxes, depreciation, and amortization (EBITDA) margins; however, management forecasts a rapid increase in top-line revenue as the integration progresses. Despite this initial margin impact, long-term prospects appear favorable.

VITAS Healthcare, Chemed's hospice subsidiary, reported growth in revenue through an increase in patient days and careful cost management in back-office operations. The company successfully recruited staff and controlled expenses, indicating no significant hiring challenges or wage pressures at present. Joel Wherley, VITAS's CEO, emphasized that the shortage of qualified healthcare workers has not posed a major issue for the company.

Roto-Rooter, on the other hand, has encountered marketing difficulties due to increased marketing costs on internet platforms and reduced organic traffic. However, the company leverages its strong brand equity, direct commercial relationships, and higher average service prices to mitigate these challenges. Kevin McNamara, Roto-Rooter's CEO, highlighted that over 50% of customers are repeat clients, reinforcing the brand's strength.

Management at Chemed closely monitors several key metrics to ensure long-term profitability, including Roto-Rooter's lead acquisition costs and VITAS Healthcare's admission mix. The company is optimistic about future growth prospects and the potential benefits of its strategic reacquisition of Roto-Rooter franchise territories. These acquisitions are expected to expand Chemed's owned branch coverage and enhance operational leverage over the next 12 to 18 months.

Ultimately, the company anticipates that Roto-Rooter will return to its historical pattern of steady margin growth as revenue increases, projecting high and sustainable growth for the foreseeable future.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

More from Tuesday 17 November →